TABLE 3.
FSGS recipient outcomes are described for SA or SF, SSO, and SWO subjects
| Outcomes | SA (n = 2395) | SF (n = 913) | SSO (n = 295) | SWO (n = 519) | All group comparison P * |
|---|---|---|---|---|---|
| n (%) | n (%) | n (%) | n (%) | ||
| Treated for rejection w/in 6 mo | <0.001a,b,d,e,f | ||||
| Yes | 152 (7.3%) | 28 (3.5%) | 52 (19.8%) | 37 (8.4%) | |
| No | 1933 (92.7%) | 781 (96.5%) | 210 (80.2%) | 406 (91.6%) | |
| Treated for rejection w/in 1 y | <0.001a,b,d,e,f | ||||
| Yes | 171 (8.2%) | 32 (4%) | 59 (22.5%) | 51 (11.5%) | |
| No | 1774 (85.1%) | 749 (92.6%) | 191 (72.9%) | 384 (86.7%) | |
| Graft failure (up to 10 y) | 185 (7.7%) | 50 (5.5%) | 50 (16.9%) | 66 (12.7%) | <0.001b,c,d,e |
| Cause of failure | 0.083 | ||||
| Recurrent disease | 46 (24.9%) | 12 (24%) | 7 (14%) | 14 (21.2%) | |
| Acute/chronic rejection | 98 (53%) | 18 (36%) | 25 (50%) | 35 (53%) | |
| Other/unknown | 40 (21.6%) | 20 (40%) | 18 (36%) | 17 (25.8%) | |
| Death with functioning graft | 81 (3.4%) | 48 (5.3%) | 15 (5.1%) | 35 (6.7%) | 0.002c |
| Death (all cause) | 94 (3.9%) | 53 (5.8%) | 22 (7.5%) | 42 (8.1%) | <0.001b,c |
| Primary graft failure, recurrent disease, and renal failure | 2 (0.1%) | 0 (0%) | 0 (0%) | 1 (0.2%) | |
| Infection | 15 (0.6%) | 8 (0.9%) | 2 (0.7%) | 6 (1.2%) | |
| Cardiovascular, cerebrovascular, and respiratory | 22 (0.9%) | 17 (1.9%) | 10 (3.4%) | 10 (1.9%) | |
| Malignancy | 12 (0.5%) | 11 (1.2%) | 3 (1%) | 6 (1.2%) | |
| Other or unknown | 42 (1.8%) | 17 (1.9%) | 6 (2%) | 18 (3.5%) | |
| Any episodes of acute rejection? | 293 (12.2%) | 83 (9.1%) | 102 (34.6%) | 89 (17.1%) | <0.001a,b,c,d,e,f |
| More than 1 episode of rejection | 53 (2.2%) | 25 (2.7%) | 28 (9.5%) | 21 (4%) | <0.001b,c,d,f |
| Disease recurrence | 161 (6.7%) | 41 (4.5%) | 33 (11.2%) | 42 (8.1%) | <0.001b,d,e |
| First rejection episode after switch | 67 (65.7%) | 73 (82.0%) |
Groups were compared by chi-square tests, 1-way ANOVA, or Kruskal-Wallis tests, and 2-tailed P values are shown. Post hoc comparisons were adjusted using Holm methods.
*Pairwise comparisons that are significant.
aSignificant post hoc pairwise comparison between SA and SF.
bSignificant post hoc pairwise comparison between SA and SSO.
cSignificant post hoc pairwise comparison between SA and SWO.
dSignificant post hoc pairwise comparison between SF and SSO.
eSignificant post hoc pairwise comparison between SF and SWO.
fSignificant post hoc pairwise comparison between SSO and SWO.
FSGS, focal segmental glomerulosclerosis; SA, steroid always; SF, steroid free; SSO, steroid switch on; SWO, steroid weaned off.